PMID- 2024540
OWN - NLM
STAT- MEDLINE
DCOM- 19910605
LR  - 20131121
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 80 Suppl 2
DP  - 1991
TI  - Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the 
      initial treatment phase of patients with congestive heart failure.
PG  - 21-7
AB  - Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the 
      adjunctive treatment of patients with congestive heart failure, cases of severe 
      hypotension, especially on the first day of treatment, have occasionally been 
      reported. To assess the safety of the ACE inhibitor enalapril a multicenter, 
      randomized, prazosin-controlled trial was designed that compared the incidence 
      and severity of symptomatic hypotension on the first day of treatment. Trial 
      medication was 2.5 mg enalapril or 0.5 prazosin. Subjects were 1210 inpatients 
      with New York Heart Association (NYHA) functional class II and III. Patients who 
      received enalapril experienced clinically and statistically significantly less 
      symptomatic hypotension (5.2%) than the patients who received prazosin (12.9%). 
      All patients recovered. It was concluded that treatment with enalapril was well 
      tolerated and it is, therefore, unreasonable to restrict the initiation of 
      treatment with enalapril to inpatients.
FAU - Hasford, J
AU  - Hasford J
AD  - Head of Research, Biometric Center for Therapeutic Studies, Munchen.
FAU - Bussmann, W D
AU  - Bussmann WD
FAU - Delius, W
AU  - Delius W
FAU - Kopcke, W
AU  - Kopcke W
FAU - Lehmann, K
AU  - Lehmann K
FAU - Weber, E
AU  - Weber E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - 69PN84IO1A (Enalapril)
RN  - XM03YJ541D (Prazosin)
SB  - IM
MH  - Aged
MH  - Enalapril/administration & dosage/*adverse effects
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Hemodynamics/*drug effects/physiology
MH  - Humans
MH  - Hypotension/*chemically induced
MH  - Male
MH  - Prazosin/administration & dosage/*adverse effects
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Kardiol. 1991;80 Suppl 2:21-7.